I'm LongbridgeAI, I can summarize articles.Zoetis (ZTS) fell 1.91% this week to $69.69, trailing the S&P 500 by roughly 1.64 percentage points. The stock opened Monday at $70.50, touched a weekly high of $71.70, and closed at $71.43 before fading. Tuesday saw a pullback to $70.30, and the stock lost ground again on Wednesday and Thursday, with Thursday’s low at $68.92. Friday brought a modest bounce off the lows, but the close of $69.69 still marked the lowest weekly close of the period. Weekly amplitude was about 4.
The Week
Zoetis (ZTS) fell 1.91% this week to $69.69, trailing the S&P 500 by roughly 1.64 percentage points. The stock opened Monday at $70.50, touched a weekly high of $71.70, and closed at $71.43 before fading. Tuesday saw a pullback to $70.30, and the stock lost ground again on Wednesday and Thursday, with Thursday’s low at $68.92. Friday brought a modest bounce off the lows, but the close of $69.69 still marked the lowest weekly close of the period. Weekly amplitude was about 4.16%, with average daily volume about 10.7% below its median.
Key Events
The week’s news flow stayed on a single downward thread. On Tuesday, Zoetis was flagged as underperforming competitors, and by Thursday the stock hit a new one-year low, drawing fresh coverage on what might come next. Friday’s reports repeated the underperformance comparison. There were no material company filings during the week, so the narrative centred on sector rotation and broad pressure on pharma rather than any product or financial update from Zoetis itself.
Analyst Ratings
A total of 17 analysts cover Zoetis: 4 rate it buy, 4 overweight, and 9 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target price is $96, implying around 37.8% upside from the latest close of $69.69. The target range is wide—$80 at the low end and $155 at the high end—pointing to a fairly split view on the stock’s upside. Zoetis ranks 11th among 203 pharmaceutical companies in industry coverage.
The Week Ahead
Early next week brings a run of US macro data: services PMI and ISM non-manufacturing PMI on Monday, followed by trade balance figures on Tuesday. For Zoetis, the bigger date is 5 November, when the company reports fiscal Q3 results before the open, with estimates at $1.41 EPS and $2.30 billion in revenue. Before that, the key question is whether the stock can hold near $69 after this week’s slide.
In Short
The signals are split. The analyst consensus is still buy, with a target price about 37.8% above spot, and valuation sits near 10.9x P/E and 9.15x P/B. Yet the stock made a new one-year low this week and large-lot money turned net seller in the latest session. The next test is the November earnings report and whether the pharma sell-off deepens as macro data lands.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.